Ofgril-OZ Tablet contains a combination of Ofloxacin 200 mg and Ornidazole 500 mg, formulated to provide broad-spectrum antimicrobial activity against a variety of bacterial and protozoal infections. Ofloxacin, a fluoroquinolone antibiotic, exerts its bactericidal effect by inhibiting bacterial DNA gyrase and topoisomerase IV, enzymes critical for DNA replication, transcription, repair, and recombination. Ornidazole, a nitroimidazole derivative, is effective against anaerobic bacteria and protozoa by disrupting DNA synthesis and causing cell death. This combination is particularly useful in treating mixed infections involving both aerobic and anaerobic organisms, such as gastrointestinal infections, genitourinary tract infections, respiratory tract infections, and certain sexually transmitted infections. Ofgril-OZ is indicated for conditions like bacterial dysentery, amoebiasis, trichomoniasis, and pelvic inflammatory disease. The dual action of Ofloxacin and Ornidazole ensures comprehensive coverage, reducing the risk of resistance development and enhancing therapeutic efficacy. It is important to use this medication under medical supervision, adhering to prescribed dosages and duration to minimize adverse effects and prevent resistance. Common side effects may include gastrointestinal disturbances, headache, dizziness, and hypersensitivity reactions. Caution is advised in patients with a history of hypersensitivity to fluoroquinolones or nitroimidazoles, and in those with hepatic or renal impairment.